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Role of circulating lipid abnormalities in chronic renal allograft rejection. (d) The vasculopathy that characterizes chronic
rejection. The evidence that circulating lipid abnormalities may renal allograft rejection is similar to that seen in heart
play a role in the pathogenesis of chronic renal allograft rejec- transplant recipients, and randomized, controlled trialstion is tantalizing but circumstantial. In animal models of car-
have reported that 3-hydroxy-3-methylglutaryl co-enzymediac and aorta allograft rejection, lipogenic diets accelerate
A (HMG-CoA) reductase inhibitors reduce cardiac allo-vascular injury, and treatment with 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors reduce vascular graft vasculopathy and prolong survival [1, 2].
injury. Histological studies have demonstrated foam cells and Although there are cogent reasons to believe that cir-
apolipoprotein deposits in the intima of arteries from chroni- culating lipid abnormalities may contribute to chroniccally rejecting human kidneys. Observational studies have
rejection, the data arguing in favor of this hypothesis arefound correlations between plasma lipid levels and both acute
largely circumstantial. Confounding the interpretationand chronic rejection. The association between lipid levels and
acute rejection in cyclosporine A (CsA)-treated renal trans- of observational data and controlled trials is the possibil-
plant recipients suggests the possibility that plasma lipids may ity that lipid levels may indirectly influence chronic rejec-
influence the immunosuppressive effects of CsA by modulating tion by altering levels of free cyclosporine A (CsA), thatthe lipoprotein-free levels of CsA. If true, such an effect could
is, CsA that is not bound to lipoproteins. Higher levelsalso explain the results of recent controlled trials showing that
of free CsA may lead to greater immunosuppression andHMG-CoA reductase inhibitors reduced graft coronary artery
disease and that they prolonged survival in heart transplant may thereby explain at least some of the relationship
recipients. In any case, the hypothesis that circulating lipid between lipid levels and renal allograft rejection.
abnormalities contribute to chronic renal allograft rejection
deserves further testing in well-designed, clinical trials.
EVIDENCE FROM ANIMAL MODELS
Lipogenic diets accelerate coronary artery disease of
Based on the results of both experimental animal in- rat and rabbit cardiac allografts in the absence of immu-
vestigations and clinical observational studies, it has been nosuppression [3, 4]. More recently Tanaka, Sukhova,
hypothesized that chronic rejection may be caused by and Libby reported that a lipogenic diet also worsened
both immune and nonimmune factors. That circulating coronary lesions in a rabbit cardiac transplant model
lipoprotein abnormalities may contribute to chronic re- immunosuppressed with CsA [5]. Similarly, a lipogenic
nal allograft rejection is suggested by several observa- diet accelerated vascular injury in a rat aorta allograft
tions: (a) Experiments using animal models of chronic model [6]. Treatment with the HMG-CoA reductase in-
rejection have suggested that lipid abnormalities may hibitors has been shown to reduce cardiac allograft vas-
contribute to allograft vasculopathy. (b) The most dis- culopathy in rats [7]. Although oxidized lipoproteins are
tinctive histological finding in chronic rejection is a form felt to be important in the pathogenesis of systemic ath-
of allograft vasculopathy that resembles, in many ways, erosclerosis, the antioxidant Probucol failed to improve
systemic atherosclerosis. (c) The same circulating lipid vascular injury in rabbit aorta allografts when cholesterol
abnormalities that have been implicated in the pathogen- levels were kept constant with diet [8].
esis of systemic atherosclerosis are common in renal
transplant recipients, and circulating lipid abnormalities
HISTOLOGICAL EVIDENCEappear to be more common in patients with chronic
The first report of successful cadaveric renal trans-
plantation in humans included a description of allograftKey words: chronic allograft rejection, transplantation, hypercholester-
olemia, HMG co-enzyme A reductase inhibitors, hyperlipidemia. vasculopathy characteristic of chronic rejection [9].
There are many similarities and differences between the 1999 by the International Society of Nephrology
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vascular lesions seen in chronic rejection and those that a functioning allograft [16]. Only 250 of the 706 patients
in this cohort ever received CsA, and most of thesecharacterize systemic atherosclerosis. The vascular le-
sions seen in chronic renal allograft rejection are made patients had the CsA electively withdrawn one year after
transplantation [17]. Using time-dependent covariatesup of macrophages, foam cells, lymphocytes, and prolif-
erating smooth muscle cells. In addition, vascular lesions in a multivariate Cox proportional hazards analysis, we
found that serum triglycerides, but not cholesterol, werefrom chronically rejecting renal allografts contain apoli-
poprotein deposits, specifically apolipoproteins A-I, independent risk factors for graft loss to chronic rejection
[16]. It is interesting to speculate whether the lack ofA-II, and B [10]. However, it is possible that arterial
lipoprotein deposition is a passive phenomenon and is effect of serum cholesterol, in contrast to the findings of
others [12, 13], could be due to the fact that few of ourthe result rather than the cause of vascular injury.
Because oxidized lipoproteins may play an important patients received long-term CsA therapy.
There is also evidence for an increased prevalence ofrole in the pathogenesis of systemic atherosclerosis, Ta-
nabe et al looked for evidence of oxidized lipoproteins oxidized lipoproteins after renal transplantation. Gha-
nem et al found that LDL particles were smaller in renalin arteries from 10 rejecting renal allografts [11]. Using a
monoclonal antibody to oxidized low-density lipoprotein transplant recipients compared with controls, suggesting
a greater tendency for LDL to become oxidized [18].(LDL), they found that four of the five individuals who
had hypercholesterolemia (.240 mg/dl) had evidence This was confirmed by showing that the lag time for
copper oxidation of LDL was reduced in transplant re-for oxidized LDL in the vascular intima. In contrast,
none of the five patients with cholesterol of less than cipients [18]. In addition, monoclonal antibodies to oxi-
dized LDL were higher in transplant recipients com-240 mg/dl had evidence for oxidized LDL in allograft
arteries [11]. Thus, it is possible that oxidized lipopro- pared with controls [18]. All of this provides strong
circumstantial evidence that oxidized LDL is more com-teins could play a role in the pathogenesis of chronic
allograft vasculopathy in hypercholesterolemic patients. mon in renal transplant recipients than in normal individ-
uals. Similarly, Cristol et al found that renal transplant
recipients with histologically confirmed chronic rejectionEVIDENCE FROM OBSERVATIONAL STUDIES
had increased plasma levels of malondialdehyde, an end
Several investigators have found that transplant recipi- product of lipid peroxidation [19].
ents with hyperlipidemia are more likely to have chronic
rejection. Isoniemi et al examined risk factors among 98
INTERVENTION TRIALSconsecutive renal allograft recipients who survived with
a functioning allograft for at least two years [12]. They Two randomized, controlled clinical trials have dem-
onstrated that HMG-CoA reductase inhibitors reducedfound that levels of total cholesterol, LDL cholesterol,
and triglycerides correlated with subsequent chronic de- the severity of angiographic coronary artery disease and
improved patient survival following cardiac transplanta-clines in allograft function. However, proteinuria was
not measured in this study, and it is possible that patients tion [1, 2]. If the pathogenesis of allograft vasculopathy
in renal and cardiac transplant recipients is similar, thendestined to have declines in function already had graft
injury that caused the elevated lipid levels. It is interest- HMG-CoA reductase inhibitors may hold promise for
preventing and/or treating chronic renal allograft rejec-ing, therefore, that Dime´ny et al found that pretransplant
cholesterol levels predicted late graft failure [13]. It was tion as well. However, the mechanism whereby HMG-
CoA reductase inhibitors improved survival in heartnoteworthy that pretransplant cholesterol levels also cor-
related with acute rejection episodes during the first six transplant recipients is still not entirely clear. It is possi-
ble that the HMG-CoA reductase inhibitors had a direct,months after transplantation [14], and acute rejection is
a strong risk factor for late graft failure. Because most immunosuppressive effect. If so, then the effect must
require the presence of CsA, as suggested by the investi-of these patients were treated with CsA, it is interesting
to speculate whether serum lipid levels influenced the gators, because there is no evidence that HMG-CoA
reductase inhibitors are immunosuppressive in normalbiological effects of CsA. Because CsA binds to lipopro-
teins, patients with lower plasma lipid levels might have individuals. However, an alternative explanation is that
the reduction in lipids caused by the HMG-CoA reduc-higher free CsA drug levels. If the free fraction is impor-
tant for cell uptake, then plasma lipid levels could influ- tase inhibitors increased the immunosuppressive effect
of CsA in the manner described earlier here. Clearly,ence the immunosuppressive and toxic effects of CsA.
Indeed, CsA toxicity may be more common in patients additional studies will be needed to understand better
the mechanisms behind the improved patient and graftwith low plasma lipid levels [15].
We examined the relationship between post-trans- survival seen with HMG-CoA reductase inhibitors. In
the meantime, it is likely that the best therapeutic ap-plant lipid levels and graft loss to chronic rejection in a
cohort of patients who survived at least six months with proach for chronic rejection may ultimately be a combi-
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Fig. 1. Potential role of antilipemic therapy
in chronic allograft rejection. 3-Hydroxy-3-
methylglutaryl co-enzyme A (HMG-CoA) re-
ductase inhibitors may decrease low density
lipoprotein cholesterol levels, which, in turn,
could theoretically increase free cyclosporine
A (CsA) levels. CsA could reduce intimal
damage by inhibiting T lymphocytes. Antioxi-
dants could reduce the formation of oxidized
low-density lipoprotein and thereby reduce
foam cell formation. Abbreviations are: LDL,
low-density lipoprotein; MP, macrophage.
probucol on transplant arteriosclerosis in aorta-allografted rabbits.nation of antilipemic, immunosuppressive, and possibly
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renal homotransplantation in the human: Report of nine cases.
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